What Is Sephience, and Why Does It Matter? Sephience (sepiapterin) is a new oral medication approved by the FDA to treat a rare inherited condition known as phenylketonuria (PKU) in adults and ...
Woman with Rare Metabolic Disorder Adopts Girl with the Same Disease: 'She's My Mini-Me' (Exclusive)
Pam Kowalcyzk and her daughter have PKU, a rare disorder that prevents the body from processing protein Wendy Grossman Kantor is an award-winning journalist who has contributed to PEOPLE for over 20 ...
Phenylketonuria (PKU) is an autosomal recessive disorder where the primary catabolic pathway for phenylalanine (Phe) is disrupted due to mutations in the gene encoding PAH. Elevated Phe levels lie ...
A Prescription Drug User Fee Act target date of February 28, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...
WARREN, N.J., April 25, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has ...
The U.S. Food and Drug Administration has approved Sephience (sepiapterin), an oral therapy by PTC Therapeutics, for the treatment of phenylketonuria (PKU), a rare inherited metabolic disorder that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results